These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 24029871

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Fibroblast growth factor 23 and the antiproteinuric response to dietary sodium restriction during renin-angiotensin-aldosterone system blockade.
    Humalda JK, Lambers Heerspink HJ, Kwakernaak AJ, Slagman MC, Waanders F, Vervloet MG, Ter Wee PM, Navis G, de Borst MH, NIGRAM Consortium.
    Am J Kidney Dis; 2015 Feb; 65(2):259-66. PubMed ID: 25278093
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial.
    Kwakernaak AJ, Krikken JA, Binnenmars SH, Visser FW, Hemmelder MH, Woittiez AJ, Groen H, Laverman GD, Navis G, Holland Nephrology Study (HONEST) Group.
    Lancet Diabetes Endocrinol; 2014 May; 2(5):385-95. PubMed ID: 24795252
    [Abstract] [Full Text] [Related]

  • 8. Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis.
    Onuigbo MA, Onuigbo NT.
    QJM; 2008 Jul; 101(7):519-27. PubMed ID: 18375475
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
    Schjoedt KJ, Jacobsen P, Rossing K, Boomsma F, Parving HH.
    Horm Metab Res; 2005 Apr; 37 Suppl 1():4-8. PubMed ID: 15918104
    [Abstract] [Full Text] [Related]

  • 11. Angiotensin I-converting enzyme and metabolism of the haematological peptide N-acetyl-seryl-aspartyl-lysyl-proline.
    Azizi M, Junot C, Ezan E, Ménard J.
    Clin Exp Pharmacol Physiol; 2001 Dec; 28(12):1066-9. PubMed ID: 11903317
    [Abstract] [Full Text] [Related]

  • 12. Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) during angiotensin-converting enzyme inhibition in humans.
    Azizi M, Ezan E, Reny JL, Wdzieczak-Bakala J, Gerineau V, Ménard J.
    Hypertension; 1999 Mar; 33(3):879-86. PubMed ID: 10082503
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Dual blockade of the renin-angiotensin-aldosterone system in cardiac and renal disease.
    Slagman MC, Navis G, Laverman GD.
    Curr Opin Nephrol Hypertens; 2010 Mar; 19(2):140-52. PubMed ID: 20051849
    [Abstract] [Full Text] [Related]

  • 16. Benefits of dietary sodium restriction in the management of chronic kidney disease.
    Krikken JA, Laverman GD, Navis G.
    Curr Opin Nephrol Hypertens; 2009 Nov; 18(6):531-8. PubMed ID: 19713840
    [Abstract] [Full Text] [Related]

  • 17. Does concurrent renin-angiotensin-aldosterone blockade in (older) chronic kidney disease patients play a role in the acute renal failure epidemic in US hospitalized patients?--Three cases of severe acute renal failure encountered in a northwestern Wisconsin Nephrology practice.
    Onuigbo MA.
    Hemodial Int; 2009 Oct; 13 Suppl 1():S24-9. PubMed ID: 19775421
    [Abstract] [Full Text] [Related]

  • 18. Sodium restriction potentiates the renoprotective effects of combined vitamin D receptor activation and angiotensin-converting enzyme inhibition in established proteinuric nephropathy.
    Mirkovic K, Frenay AS, van den Born J, van Goor H, Navis G, de Borst MH, NIGRAM consortium.
    Nephrol Dial Transplant; 2017 Aug 01; 32(8):1293-1301. PubMed ID: 26311058
    [Abstract] [Full Text] [Related]

  • 19. Sodium intake, RAAS-blockade and progressive renal disease.
    de Borst MH, Navis G.
    Pharmacol Res; 2016 May 01; 107():344-351. PubMed ID: 27041482
    [Abstract] [Full Text] [Related]

  • 20. Urinary renin, but not angiotensinogen or aldosterone, reflects the renal renin-angiotensin-aldosterone system activity and the efficacy of renin-angiotensin-aldosterone system blockade in the kidney.
    van den Heuvel M, Batenburg WW, Jainandunsing S, Garrelds IM, van Gool JM, Feelders RA, van den Meiracker AH, Danser AH.
    J Hypertens; 2011 Nov 01; 29(11):2147-55. PubMed ID: 21941204
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.